Enzalutamide
C3431046 NON- INTERVENTIONAL STUDY PROTOCOL
Version [ADDRESS_109369] 2022
PFIZER CONFIDENTIAL
Page 44of 4715.REFERENCES
1. National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. 2021; 
https://seer.cancer.gov/statfacts/html/prost.html . Accessed July  21, 2021.
2. National Cancer Institute. Prostate cancer treatment: health professional version. 
2016; http://www.cancer.gov/types/prostate/hp/prostate -treatment -pdq. Accessed July  
21, 2021.
3. Kirby  M, Hirst C, Crawford ED. Characterising the castration -resistant prostate 
cancer population: a s ystematic review. Int J Clin Pract. 2011;65(11):1180 -1192.
4.
He L, Fang H, Chen C, et al. Metastatic castration- resistant prostate cancer: 
Academic insights and perspectives through bibliometric anal ysis. Medicine 
(Baltimore). 2020;99(15):e19760.
5. National Comprehensive Cancer Network. Prostate Cancer. . 2021 ; Version 
2.2021: https://www.nccn.org/professionals/ph ysician_gls/pdf/prostate.pdf . Accessed 
July 21, 2021.
6. Sweeney  CJ, Chen YH, Carducci M, et al. Chemohormonal Therap y in Metastatic 
Hormone -Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737 -746.
7. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherap y-
naive metastatic castration -resistant prostate cancer: extended anal ysis of the phase 3 
PREVAIL stud y. European urology. 2017;71(2):151-154.
8. Moreira DM, Howard LE, Sourb eer KN, et al. Predicting Time From Metastasis to 
Overall Survival in Castration- Resistant Prostate Cancer: Results From SEARCH. 
Clin Genitourin Cancer. 2017;15(1):60 -66 e62.
9. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus
placebo plus prednisone in chemotherap y-naive men with metastatic castration -
resistant prostate cancer (COU- AA-302): final overall survival anal ysis of a 
randomised, double -blind, placebo -controlled phase 3 study . Lancet Oncol. 
2015;16(2):152 -
160.
10. Tannock IF, de Wit R, Berry  WR, et al. Docetaxel plus prednisone or mitoxantrone 
plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-
1512.
11. de Bono JS, L ogothetis CJ, Molina A, et al. Abiraterone and increased survival in 
metastat ic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
12. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer 
without previous chemotherap y. N Engl J Med. 2013;368(2):138 -148.
13. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate 
cancer after chemotherapy. N Engl J Med. 2012;367(13):[ADDRESS_109370]- line 
therap y for patients with metastatic castration -resistant prostat e cancer: a randomized 
phase III trial —FI RSTANA. Journal of Clinical Oncology. 2017;35(28):3189-3197.
15.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel- T immunotherap y for 
castration -resistant prostate cancer. N Engl J Med. 2010;363(5):411 -
422.
16. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium -223 and survival in 
metastatic prostate cancer. New England Journal of Medicine. 2013;369(3):[ADDRESS_109371] 2022
PFIZER CONFIDENTIAL
Page 45of 4717. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration- resistant 
prostate cancer. N Engl J Med. 2020;382(22):2091-2102.
18. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration -
resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. Journal of 
Clinical Oncology. 2020;38(32):3763.
19. Astellas Pharma US. XTANDI [package insert]. 2012; 
https://www.astellas.us/docs/us/12A005 -ENZ -WPI.pdf . Accessed July  21, 2021.
20. Janssen Global Services LLC. ZYTIGA [package insert]. 2011; 
https://www.janssenlabels.com/package -insert/product -monograph/prescribing -
information/ZYTIGA -pi.pdf . Accessed July  21, 2021.
21. George DJ, Sartor O, Miller K, et al. Treatment Patterns and Outcomes in Patients 
With Metastatic Castration -resistant Prostat e Cancer in a Real -world Clinical Practice 
Setting in the [LOCATION_002]. Clin Genitourin Cancer. 2020;18(4):[ADDRESS_109372] -Line 
Treatment of Metastatic Castration- Resistant Prostate Cancer : The Prostate Cancer 
Registry . Target Oncol. 2020;15(3):301 - 315.
23. Ternov et al. EAU 2021: Fatigue, Quality -of-Life and Metabolic Changes in Men 
Treated With Enzalutamide Versus Abiraterone Plus Prednisone (HEAT): A 
Randomized Trial. 2021; https://www.urotoday .com/conference- highlights/eau -
2021/eau-2021- prostate -cancer/[ADDRESS_109373], 2021.
24. Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and 
abiraterone acetate plus prednisone in metastatic castration -resistant prostate cancer: a 
multicentre, randomised, open -label, phase 2, crossover trial. Lancet Oncol. 
2019;20(12):1730-1739.
25. Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or Enzalutamide 
in Advanced Castration -Resistant Prostate Cancer: An I ndirect Comparison. Prostate. 
2017;77(6):639 -646.
26. Fang M, Nakazawa M, Antonarakis ES, L i C. Efficac y of Abiraterone and 
Enzalutamide in Pre -and Postdocetaxel Castration -Resistant Prostate Cancer: A 
Trial -Level Meta -Anal ysis. Prostate Cancer. 2017;2017:8560827.
27. McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S. Sy stematic 
review and n etwork meta -analysis of treatments for chemotherapy -naive patients with 
asymptomatic/mildly  symptomatic metastatic castration -resistant prostate cancer. 
Value in Health. 2018;21(10):1259 -1268.
28. Raju R, Sahu A, Klevansky  M, Torres J. Real -World Data on O utcomes in Metastatic 
Castrate -Resistant Prostate Cancer Patients Treated With Abiraterone or 
Enzalutamide: A Regional Experience. Front Oncol. 2021;11:656146.
29. Scailteux L -M, Campi[INVESTIGATOR_99265] -Gimenez B, Kerbrat S, et al. Overall Survival Among 
Chemotherap y-Naive Patients With Castration- Resistant Prostate Cancer Under 
Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014 –2018 
French Population Study  (the SPEAR Cohort). Am J Epi[INVESTIGATOR_5541]. 2021;190(3):[ADDRESS_109374] 2022
PFIZER CONFIDENTIAL
Page 46of 4730. Schoen MW, Carson KR, L uo S, et al. S urvival of veterans treated with enzalutamide 
and abiraterone in advanced prostate cancer. In: Wolters Kluwer Health; 2021.
31. Soleimani M, Zou K, Sunderland K, et al. Effectiveness of first- line abiraterone 
versus enzalutamide among patients >/=80 years of age with metastatic castration-
resistant prostate cancer: A retrospective propensity  score -weighted comparative 
cohort study . Eur J Cancer. 2021;152:[ADDRESS_109375] -Line Abiraterone. JAMA network open. 
2022;5(1):e2142093 -e2142093.
34. Jarow JP, LaVange L, Woodcock J. Multidimensional Evidence Generation and FDA 
Regulatory  Decision Making: Defining and Using "Real -
World" Data. JAMA. 
2017;318(8):703 -704.
35. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real- world evidence —what is it and 
what can it tell us. N Engl J Med. 2016;375(23):2293
-2297.
36. U.S. Food and Drug Administration. Framework for FDA's Real-World Evidence 
program. 2018; https://www.fda.gov/media/120060/download . Accessed September 
27, 2019.
37. US Food and Drug Administration. Submitting Documents Using Real- World Data 
and Real -World Evidence to FDA for Drugs and Biologics. Draft Guidan ce for 
Industry . 2019; https://www.fda.gov/media/124795/download .
38. Administration SS. GN [ZIP_CODE].005 Preferred Evidence of Death. 2019; TN 20 (04 -
19):https://secure.ssa.gov/poms.nsf/lnx/[PHONE_2289]. . Accessed July  21, 2021.
39. Administration SS. GN [ZIP_CODE] .001 Proof of Death Requirements. Program 
Operations Manual System (POMS) 2020; TN 21 (10-
20):https://secure.ssa.gov/poms.NSF/lnx/[PHONE_2290] . Accessed July  21, 2021.
40. Administration SS. Requesting SSA’s Death Information. 2021; 
https://www.ssa.gov/datae xchange/request_dmf.html . Accessed July  21, 2021.
41. Center CRDA. Data Documentation -Master Beneficiary  Summary  File Base. 2019; 
https://resdac.org/cms -data/files/mbsf -base/data -documentation .
42. Fizazi KT, Namphuong; Fein, Luis Enrique; et al. . L ATITUDE: A phase III, double -
blind, randomized trial of androgen deprivation therap y with abiraterone acetate plus 
prednisone or placebos in newly  diagnosed high- risk metastatic hormone -naive 
prostate can cer. J Clin Oncol. 2017.
43. Fizazi K, Tran N, Fein L , et al. Abiraterone acetate plus prednisone in patients with 
newly  diagnosed high- risk metastatic castration -sensitive prostate cancer 
(LATITUDE): final overall survival anal ysis of a randomised, double -blind, phase 3 
trial. Lancet Oncol. 2019;20(5):686-700.
44. Mues KE, L iede A, L iu J, et al. Use of the Medicare database in epi[INVESTIGATOR_99266]: a valuable source of real -world evidence on the older and 
disabled populations in the U S. Clin Epi[INVESTIGATOR_5541]. 2017;9:267-277.

Enzalutamide
C3431046 NON- INTERVENTIONAL STUDY PROTOCOL
Version [ADDRESS_109376] 2022
PFIZER CONFIDENTIAL
Page 47of 4745. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic 
castration -resistant prostate cancer: final overall survival anal ysis of the COU -AA-
301 randomised, double -blind, placebo -controlled phase 3 study . Lancet Oncol. 
2012;13(10):983 -
992.
46. Wallace K, Landsteiner A, Bunner S, Engel -Nitz N, L uckenbaugh A. Epi[INVESTIGATOR_99267]-resistant prostate cancer (mCRPC) in a 
managed care population in the [LOCATION_002]. In: American Societ y of Clinical 
Oncology ; 2020.
47. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal 
inference in epi[INVESTIGATOR_623] . Epi[INVESTIGATOR_623]. 2000;11(5):550 -560.
48. Cole SR, Hernan MA. Constructing inverse probability  weights for marginal 
structural models. Am J Epi[INVESTIGATOR_5541]. 2008;168(6):656 -664.
49. Austin PC. An I ntroduction to Propensity  Score Methods for Reducing the Effects of 
Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
